JP2021500336A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021500336A5 JP2021500336A5 JP2020521860A JP2020521860A JP2021500336A5 JP 2021500336 A5 JP2021500336 A5 JP 2021500336A5 JP 2020521860 A JP2020521860 A JP 2020521860A JP 2020521860 A JP2020521860 A JP 2020521860A JP 2021500336 A5 JP2021500336 A5 JP 2021500336A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- dose
- subject
- combination according
- hu5f9
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022186496A JP7474827B2 (ja) | 2017-10-18 | 2022-11-22 | 抗ｃｄ４７及び抗ｐｄ－ｌ１による卵巣癌の処置 |
| JP2024003136A JP2024024121A (ja) | 2017-10-18 | 2024-01-12 | 抗ｃｄ４７及び抗ｐｄ－ｌ１による卵巣癌の処置 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762574073P | 2017-10-18 | 2017-10-18 | |
| US62/574,073 | 2017-10-18 | ||
| PCT/US2018/056442 WO2019079549A1 (en) | 2017-10-18 | 2018-10-18 | TREATMENT OF OVARY CANCER BY ANTI-CD47 AND ANTI-PD-L1 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022186496A Division JP7474827B2 (ja) | 2017-10-18 | 2022-11-22 | 抗ｃｄ４７及び抗ｐｄ－ｌ１による卵巣癌の処置 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021500336A JP2021500336A (ja) | 2021-01-07 |
| JP2021500336A5 true JP2021500336A5 (enExample) | 2021-10-07 |
| JP7308190B2 JP7308190B2 (ja) | 2023-07-13 |
Family
ID=64402251
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020521860A Active JP7308190B2 (ja) | 2017-10-18 | 2018-10-18 | 抗ｃｄ４７及び抗ｐｄ－ｌ１による卵巣癌の処置 |
| JP2022186496A Active JP7474827B2 (ja) | 2017-10-18 | 2022-11-22 | 抗ｃｄ４７及び抗ｐｄ－ｌ１による卵巣癌の処置 |
| JP2024003136A Withdrawn JP2024024121A (ja) | 2017-10-18 | 2024-01-12 | 抗ｃｄ４７及び抗ｐｄ－ｌ１による卵巣癌の処置 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022186496A Active JP7474827B2 (ja) | 2017-10-18 | 2022-11-22 | 抗ｃｄ４７及び抗ｐｄ－ｌ１による卵巣癌の処置 |
| JP2024003136A Withdrawn JP2024024121A (ja) | 2017-10-18 | 2024-01-12 | 抗ｃｄ４７及び抗ｐｄ－ｌ１による卵巣癌の処置 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210047416A1 (enExample) |
| EP (2) | EP4194470A1 (enExample) |
| JP (3) | JP7308190B2 (enExample) |
| KR (1) | KR20200070341A (enExample) |
| CN (1) | CN111315783A (enExample) |
| AU (1) | AU2018351007B2 (enExample) |
| CA (1) | CA3078430A1 (enExample) |
| ES (1) | ES2938652T3 (enExample) |
| PL (1) | PL3697819T3 (enExample) |
| PT (1) | PT3697819T (enExample) |
| SI (1) | SI3697819T1 (enExample) |
| WO (1) | WO2019079549A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2796378T3 (es) | 2016-01-11 | 2020-11-26 | Forty Seven Inc | Anticuerpos monoclonales anti-cd47 humanizados, de ratón o químicos |
| US11802153B2 (en) | 2017-10-18 | 2023-10-31 | Forty Seven, Inc. | Anti-CD47 agent-based ovarian cancer therapy |
| EP4129336B1 (en) | 2018-02-12 | 2025-05-07 | Forty Seven, LLC | Anti-cd47 agent-based treatment of cd20-positive cancer |
| WO2020233539A1 (en) * | 2019-05-17 | 2020-11-26 | Nanjing GenScript Biotech Co., Ltd. | Anti-cd47/anti-pd-l1 multiple antigen binding proteins and methods of use thereof |
| AU2020410410A1 (en) | 2019-12-17 | 2022-06-09 | Pfizer Inc. | Antibodies specific for CD47, PD-L1, and uses thereof |
| CN120437288A (zh) * | 2019-12-24 | 2025-08-08 | 正大天晴药业集团南京顺欣制药有限公司 | 治疗卵巢癌的药物组合 |
| TWI855236B (zh) * | 2020-02-28 | 2024-09-11 | 大陸商南京聖和藥業股份有限公司 | 抗cd47/抗pd-l1抗體及其應用 |
| WO2022148411A1 (zh) * | 2021-01-08 | 2022-07-14 | 北京韩美药品有限公司 | 抗pd-l1/抗cd47天然抗体结构样异源二聚体形式双特异抗体及其制备 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160095939A1 (en) * | 2014-10-07 | 2016-04-07 | Immunomedics, Inc. | Neoadjuvant use of antibody-drug conjugates |
| JP6166177B2 (ja) | 2010-05-14 | 2017-07-19 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | Ｃｄ４７に対するヒト化及びキメラモノクローナル抗体 |
| ES2728066T3 (es) | 2013-03-15 | 2019-10-22 | Univ Leland Stanford Junior | Métodos para la obtención de dosis terapéuticamente eficaces de agentes anti-CD47 |
| TWI595006B (zh) * | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| WO2017019767A1 (en) * | 2015-07-27 | 2017-02-02 | Myosotis, Llc | Inhibition of CXCL12 in Cancer Immunotherapy |
| WO2017049251A2 (en) * | 2015-09-18 | 2017-03-23 | Tioma Therapeutics, Inc. | Therapeutic cd47 antibodies |
| BR112018013094A2 (pt) * | 2015-12-28 | 2018-12-11 | Merck Patent Gmbh | combinação de inibidor de hdac e anticorpo de anti-pd-l1 para o tratamento de câncer ovariano |
| CN109071676A (zh) * | 2016-01-21 | 2018-12-21 | 小利兰·斯坦福大学托管委员会 | 使用免疫调节剂的组合的癌症治疗 |
-
2018
- 2018-10-18 EP EP22207465.0A patent/EP4194470A1/en active Pending
- 2018-10-18 JP JP2020521860A patent/JP7308190B2/ja active Active
- 2018-10-18 EP EP18807145.0A patent/EP3697819B1/en active Active
- 2018-10-18 AU AU2018351007A patent/AU2018351007B2/en active Active
- 2018-10-18 CN CN201880071877.6A patent/CN111315783A/zh active Pending
- 2018-10-18 KR KR1020207014146A patent/KR20200070341A/ko not_active Ceased
- 2018-10-18 PL PL18807145.0T patent/PL3697819T3/pl unknown
- 2018-10-18 SI SI201830820T patent/SI3697819T1/sl unknown
- 2018-10-18 PT PT188071450T patent/PT3697819T/pt unknown
- 2018-10-18 ES ES18807145T patent/ES2938652T3/es active Active
- 2018-10-18 US US16/756,790 patent/US20210047416A1/en not_active Abandoned
- 2018-10-18 WO PCT/US2018/056442 patent/WO2019079549A1/en not_active Ceased
- 2018-10-18 CA CA3078430A patent/CA3078430A1/en active Pending
-
2022
- 2022-11-22 JP JP2022186496A patent/JP7474827B2/ja active Active
-
2024
- 2024-01-12 JP JP2024003136A patent/JP2024024121A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021500336A5 (enExample) | ||
| KR102329584B1 (ko) | 종양 치료용 항-ｂ7-ｈ1 항체 | |
| JP2021500349A5 (enExample) | ||
| JP2009539841A (ja) | 自己免疫疾患の治療における抗ｃｄ３抗体の投与 | |
| Bautista et al. | Hypersensitivity reaction and acute immune-mediated thrombocytopenia from oxaliplatin: two case reports and a review of the literature | |
| TW201731527A (zh) | 使用抗ｐｄ－１抗體與抗ｃｌｔａ－４抗體之組合以治療肺癌 | |
| CN115942973A (zh) | 用于黑色素瘤的lag-3拮抗剂疗法 | |
| US20210292415A1 (en) | Methods of treating a tumor | |
| TW202529804A (zh) | 用於癌症治療的組合療法 | |
| TW202207976A (zh) | 使用免疫檢查點抑制劑抗體治療癌症之方法和組合 | |
| CN119055767A (zh) | 包含抗her2双特异性抗体的联合治疗药物及其用途 | |
| WO2023147371A1 (en) | Combination therapy for hepatocellular carcinoma | |
| EP3870288B1 (en) | Pan-elr+ cxc chemokine antibodies for the treatment of hidradenitis suppurativa | |
| TW202228772A (zh) | 藉由併用阿替利珠單抗、托珠單抗、吉西他濱、白蛋白結合紫杉醇之4劑的胰臟癌治療劑 | |
| EP4595980A1 (en) | Method for treating membranous nephropathy with taci-fc fusion protein | |
| US20250332252A1 (en) | Antibody compositions and methods of use thereof | |
| WO2023164662A1 (en) | Treatment of squamous non small cell lung cancer | |
| WO2024099387A1 (zh) | 通过施用配体-药物偶联体治疗癌症 | |
| WO2024193675A1 (zh) | 通过施用配体-药物偶联体治疗卵巢癌 | |
| CN119630418A (zh) | 抗GARP-TGF-β1/PD-1组合疗法 | |
| JPWO2022076767A5 (enExample) | ||
| CN119300862A (zh) | 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途 | |
| CN116568307A (zh) | 用于肺癌的lag-3拮抗剂疗法 | |
| CN120456895A (zh) | 使用结合egfr的抗体与细胞毒性药物的组合的癌症治疗 | |
| CN121003695A (zh) | 抗tigit抗体和抗pd-1抗体联合治疗肿瘤 |